MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Johnson and Johnson

Atvērts

SektorsVeselības aprūpe

153.18 -7.5

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

154.02

Max

165.34

Galvenie mērījumi

By Trading Economics

Ienākumi

3.4B

Pārdošana

20M

23B

P/E

Sektora vidējais

28.153

73.239

EPS

2.04

Dividenžu ienesīgums

3.03

Peļņas marža

15.235

Darbinieki

138,100

EBITDA

652M

5.9B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+0.92% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.03%

3.06%

Nākamie ieņēmumi

2025. g. 15. apr.

Nākamais Ex dividenžu datums

2025. g. 19. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

26B

394B

Iepriekšējā atvēršanas cena

160.68

Iepriekšējā slēgšanas cena

153.18

Ziņu noskaņojums

By Acuity

46%

54%

152 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Johnson and Johnson Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 10. marts 15:16 UTC

Galvenie tirgus virzītāji

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

2025. g. 10. marts 13:59 UTC

Galvenie tirgus virzītāji

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

2025. g. 21. marts 23:02 UTC

Iegādes, apvienošanās, pārņemšana

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

2025. g. 21. marts 13:35 UTC

Peļņas
Karstas akcijas

Stocks to Watch Friday: J&J, Nike, FedEx, Micron -- WSJ

2025. g. 14. marts 09:30 UTC

Top Ziņas

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

2025. g. 7. marts 01:00 UTC

Top Ziņas

Finance Executives Seek Stability Amid Erratic Tariff Shifts -- WSJ

2025. g. 18. febr. 22:22 UTC

Top Ziņas

Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan -- Update

2025. g. 14. febr. 13:00 UTC

Top Ziņas

J&J's High Hopes for Heart-Rhythm Device Grounded by Safety Concerns -- WSJ

2025. g. 24. janv. 07:00 UTC

Top Ziņas

Disasters Spawn New Businesses. The California Wildfires Will Do the Same. -- Barrons.com

2025. g. 22. janv. 21:39 UTC

Peļņas

These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

2025. g. 22. janv. 19:41 UTC

Peļņas

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

2025. g. 22. janv. 17:38 UTC

Tirgus saruna
Peļņas

J&J's Forex Headwind in Outlook Surprised Investors -- Market Talk

2025. g. 22. janv. 16:48 UTC

Peļņas

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

2025. g. 22. janv. 14:51 UTC

Peļņas

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Ford, and More -- Barrons.com

2025. g. 22. janv. 14:09 UTC

Top Ziņas
Peļņas

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

2025. g. 22. janv. 13:04 UTC

Peļņas

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Travelers, and More -- Barrons.com

2025. g. 22. janv. 12:47 UTC

Peļņas

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Agilysys, and More -- Barrons.com

2025. g. 22. janv. 12:34 UTC

Peļņas

Johnson & Johnson Earnings Narrowly Top But Dow Giant's Sales Guidance Light -- IBD

2025. g. 22. janv. 12:15 UTC

Tirgus saruna

J&J's 2025 Sales View Misses Wall Street Estimates -- Market Talk

2025. g. 22. janv. 11:57 UTC

Tirgus saruna
Peļņas

J&J 4Q Sales Rise on Demand for Cancer Drugs, Medical Devices -- Market Talk

2025. g. 22. janv. 11:30 UTC

Peļņas

J&J's Earnings Beat Estimates But Guidance Is Mixed -- MarketWatch

2025. g. 22. janv. 11:23 UTC

Top Ziņas
Peļņas

J&J Reports Strong Revenue and Profit But Faces Challenges in 2025 -- WSJ

2025. g. 22. janv. 11:22 UTC

Top Ziņas
Peļņas

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

2025. g. 22. janv. 11:20 UTC

Peļņas

Johnson & Johnson: Innovative Medicine 4Q Results Driven by In-Market Portfolio and Continued Uptake From Recently Launched Products, With 10 Brands Growing Double Digits >JNJ

2025. g. 22. janv. 11:20 UTC

Peļņas

Johnson & Johnson 4Q Worldwide MedTech Sales $8.19B >JNJ

2025. g. 22. janv. 11:20 UTC

Peļņas

Johnson & Johnson 4Q U.S. Sales $13.20B >JNJ

2025. g. 22. janv. 11:20 UTC

Peļņas

Johnson & Johnson: MedTech Business, With Addition of Shockwave Medical, Delivered Operational Sales Growth of 7.6% in 4Q >JNJ

2025. g. 22. janv. 11:20 UTC

Peļņas

Johnson & Johnson Sees 2025 Operational Sales of $90.9B-$91.7B >JNJ

2025. g. 22. janv. 11:20 UTC

Peļņas

Johnson & Johnson Sees 2025 Adjusted Operational EPS $10.75-$10.95 >JNJ

2025. g. 22. janv. 11:20 UTC

Peļņas

Johnson & Johnson Sees 2025 Adjusted Operational Sales Growth of 2.0%-3.0% >JNJ

Salīdzinājums

Cenas izmaiņa

Johnson and Johnson Prognoze

Cenas mērķis

By TipRanks

0.92% augšup

Prognoze 12 mēnešiem

Vidējais 167.36 USD  0.92%

Augstākais 185 USD

Zemākais 152 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Johnson and Johnson  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

13 ratings

5

Pirkt

8

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

162.84 / N/AAtbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

152 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.